MARLBOROUGH, Mass.--(BUSINESS WIRE)--EXACT Sciences Corporation (Nasdaq: EXAS) announced today that it has signed a letter of intent with Laboratory Corporation of America Holdings (LabCorp®) to further strengthen and expand their relationship related to EXACT’s proprietary stool-based DNA technologies for colorectal cancer (CRC) screening. Under the new relationship, LabCorp will assume sole responsibility, at its expense, for all commercial activities including marketing, sales, and reimbursement related to its stool-based CRC testing service.
